Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 12;13(7):644.
doi: 10.3390/antibiotics13070644.

What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study

Aurélien Dinh  1 , Guillaume Béraud  2 , Johan Courjon  3 , Yann Le Goff  4 , Nicolas Kader Ettahar  5 , Matthieu Grégoire  6 , Eric Senneville  7
Affiliations

What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study

Aurélien Dinh et al. Antibiotics (Basel). .

Abstract

Objectives: To identify the current practices with long half-life lipoglycopeptides (LGPs) and potential use/position of oritavancin.

Results: Despite their indication being limited to skin and soft tissue infections (SSTIs), long half-life lipoglycopeptides are mainly used off-label to treat bone and joint infections (BJIs) and infective endocarditis. Oritavancin and dalbavancin are both semisynthetic lipoglycopeptide antibiotics with activity against Gram-positive organisms. The game-changing property of these two antibiotics is their one-time dosing. Due to its shorter half-life, oritavancin might have an advantage over dalbavancin for a treatment duration of less than 2 weeks, as it could be used both in prolonged treatments of complicated patients in BJIs or administered as a single-dose treatment for Gram-positive cocci infections usually treated by a 5- to 10-day antibiotic course. These infections include urinary tract infections, bacteremias, catheter-related infections, etc. In addition to the possibility of being used as an end-of-treatment injection, oritavancin could be used as an empiric therapy treatment in the postoperative period in the context of device-associated especially prosthetic joint infections to allow for the early discharge of the patient.

Methods: A qualitative survey was conducted in March 2022 including sixteen infectiologists, one internist, five hospital pharmacists, and one pharmacologist.

Conclusion: Long half-life lipoglycopeptides contribute to changing the paradigm in the management of acute bacterial infections, as infectiologists now consider a range of indications and patient profiles for one single drug. Oritavancin strengthens the therapeutic arsenal in numerous infections from BJIs to urinary tract infections and could help to manage specific clinical situations, on top of providing potential benefits for the hospital's budget.

Keywords: Gram-positive; acute bacterial infections; hospital discharge; long half-life lipoglycopeptides; long-acting antibiotics; oritavancin.

PubMed Disclaimer

Conflict of interest statement

Aurélien Dinh has received a speaker honorarium from Menarini, MSD, Shionogi, Pfizer, and Sanofi. Johan Courjon has received a speaker honorarium from Advanz Pharma, and Menarini. Guillaume Béraud has received a speaker honorarium from Menarini, Pfizer, Gilead, MSD, GSK, and AdvanzPharma. Yann Le Goff has no conflicts of interest to report. Nicolas Kader Ettahar has received a speaker honorarium from Menarini. Matthieu Grégoire has received a speaker honorarium from Menarini, Shionogi, AdvanzPharma, Gilead, Janssen, MSD, Pfizer, and Viiv. Eric Senneville has received a speaker honorarium from Menarini, MSD, Shionogi, Pfizer, Sanofi, Debiopharm, and AdvanzPharma.

Figures

Figure 1
Figure 1
Sample description.
Figure 2
Figure 2
Indications (Supplementary Materials, File S1).
Figure 3
Figure 3
Patient profiles and/or clinical factors.
See this image and copyright information in PMC

References

    1. Rubino C.M., Bhavnani S.M., Moeck G., Bellibas S.E., Ambrose P.G. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob. Agents Chemother. 2015;59:3365–3372. doi: 10.1128/AAC.00176-15. - DOI - PMC - PubMed
    1. Ambrose P.G., Drusano G.L., Craig W.A. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2012;54((Suppl. 3)):S220–S228. doi: 10.1093/cid/cis001. - DOI - PubMed
    1. Corey G.R., Kabler H., Mehra P., Gupta S., Overcash J.S., Porwal A., Giordano P., Lucasti C., Perez A., Good S., et al. Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. N. Engl. J. Med. 2014;370:2180–2190. doi: 10.1056/NEJMoa1310422. - DOI - PubMed
    1. Zhanel G.G., Schweizer F., Karlowsky J.A. Oritavancin: Mechanism of action. Clin. Infect Dis. 2012;54:214–219. doi: 10.1093/cid/cir920. - DOI - PubMed
    1. Dunbar L.M., Milata J., McClure T., Wasilewski M.M., The SIMPLIFI Study Team Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: An Analysis of the SIMPLIFI Trial. Antimicrob. Agents Chemother. 2011;55:3476–3484. doi: 10.1128/AAC.00029-11. - DOI - PMC - PubMed

LinkOut - more resources